Protocol Ledger

NCT05318573 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT05318573 sponsored by Fujifilm Pharmaceuticals U.S.A in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-01 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05318573
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05318573
Protocol FieldVerified Registry Value
NCT IdentifierNCT05318573
Consolidated Lead SponsorFujifilm Pharmaceuticals U.S.A
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2022-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05318573
Hospital Research SiteLocationSite Profile
Sibley Memorial HospitalWashington D.C, DCOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->
NYU Langone Health and Perlmutter Cancer CenterNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI